董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sean E. Browne | 男 | Chief Executive Officer and Director and President | 60 | 135.17万美元 | 未持股 | 2026-02-28 |
| Jonn R. Beeson | 男 | Director | 56 | 18.57万美元 | 未持股 | 2026-02-28 |
| Abhinav Jain | 男 | Director | 35 | 13.12万美元 | 未持股 | 2026-02-28 |
| Tyler P. Lipschultz | 男 | Director | 58 | 13.38万美元 | 未持股 | 2026-02-28 |
| Stavros G. Vizirgianakis | 男 | Chairman of the Board and Director | 55 | 47.71万美元 | 未持股 | 2026-02-28 |
| John K. Bakewell | 男 | Director | 64 | 18.53万美元 | 未持股 | 2026-02-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sean E. Browne | 男 | Chief Executive Officer and Director and President | 60 | 135.17万美元 | 未持股 | 2026-02-28 |
| Scott C. Neils | 男 | Assistant Secretary and Chief Financial Officer | 41 | 93.94万美元 | 未持股 | 2026-02-28 |
| Mark A. Schallenberger | 男 | Chief Operating Officer | 40 | 111.05万美元 | 未持股 | 2026-02-28 |
董事简历
中英对照 | 中文 | 英文- Sean E. Browne
-
SeanE.Browne于2019年10月7日被任命为我们的总裁兼首席执行官，并自2019年10月30日起担任董事会成员。在此之前，Browne先生于2014年9月至2019年6月担任上门医疗用品提供商CCS Medical，Inc.的首席营收官。加入CCS Medical之前，Browne从2013年3月到2014年8月担任Kini Group（一家集成的基于云的软件分析和咨询公司）首席运营官。从2007年11月至2016年3月，Browne先生担任Neuro Resource Group的总裁兼首席执行官兼董事，Neuro Resource Group是一家风险初创医疗设备公司，已出售给战略买家。在其他职位上，布朗先生曾担任Integra Lifesciences Holdings Corporation Miltex手术器械部门的总裁，该公司是一家上市医疗设备公司，收购了Miltex Holdings，Inc.。Browne先生曾担任eSurg.com的销售与市场营销Vice President，这是一家为医生和门诊手术市场提供服务的电子商务公司。在加入eSurg.com之前，Browne先生曾担任麦克森公司公司（一家制药公司）的高级副总裁，健康系统部，在加入McKesson公司之前，他曾在百特梦百合公司担任多个职位，并承担越来越多的责任。Browne先生拥有西北大学凯洛格管理学院（Kellogg School of Management at Northwestern University）的工商管理硕士学位和波士顿大学（Boston University）的理学士学位，主修金融和辅修统计学。
Sean E. Browne has served as Xtant Medical Holdings, Inc.'s President and Chief Executive Officer since October 2019 and as a member of Xtant Medical Holdings, Inc.'s Board since October 2019. Prior to this, Mr. Browne served as Chief Revenue Officer of CCS Medical, Inc., a provider of home delivery medical supplies, from September 2014 to June 2019. Prior to CCS Medical, Mr. Browne served as Chief Operating Officer of The Kini Group, an integrated cloud based software analytics and advisory firm, from March 2013 to August 2014. From November 2007 to March 2016, Mr. Browne served as President and Chief Executive Officer and a director of Neuro Resource Group, a venture start up medical device company that was sold to a strategic buyer. In other roles, Mr. Browne served as President, Miltex Surgical Instrument Division for Integra LifeSciences Holdings Corporation, a publicly held medical device company that acquired Miltex Holdings, Inc. Mr. Browne served as Vice President, Sales and Marketing of Esurg.com, an e commerce company serving physician and ambulatory surgery markets. Prior to Esurg.com, Mr. Browne served as Senior Vice President, Health Systems Division of McKesson Corporation, a drug company, and prior to McKesson, served in various positions with increasing responsibility at Baxter Healthcare. Mr. Browne holds a Master of Business Administration from the Kellogg School of Management at Northwestern University and a Bachelor of Science degree, with a major in Finance and minor in Statistics, from Boston University. - SeanE.Browne于2019年10月7日被任命为我们的总裁兼首席执行官，并自2019年10月30日起担任董事会成员。在此之前，Browne先生于2014年9月至2019年6月担任上门医疗用品提供商CCS Medical，Inc.的首席营收官。加入CCS Medical之前，Browne从2013年3月到2014年8月担任Kini Group（一家集成的基于云的软件分析和咨询公司）首席运营官。从2007年11月至2016年3月，Browne先生担任Neuro Resource Group的总裁兼首席执行官兼董事，Neuro Resource Group是一家风险初创医疗设备公司，已出售给战略买家。在其他职位上，布朗先生曾担任Integra Lifesciences Holdings Corporation Miltex手术器械部门的总裁，该公司是一家上市医疗设备公司，收购了Miltex Holdings，Inc.。Browne先生曾担任eSurg.com的销售与市场营销Vice President，这是一家为医生和门诊手术市场提供服务的电子商务公司。在加入eSurg.com之前，Browne先生曾担任麦克森公司公司（一家制药公司）的高级副总裁，健康系统部，在加入McKesson公司之前，他曾在百特梦百合公司担任多个职位，并承担越来越多的责任。Browne先生拥有西北大学凯洛格管理学院（Kellogg School of Management at Northwestern University）的工商管理硕士学位和波士顿大学（Boston University）的理学士学位，主修金融和辅修统计学。
- Sean E. Browne has served as Xtant Medical Holdings, Inc.'s President and Chief Executive Officer since October 2019 and as a member of Xtant Medical Holdings, Inc.'s Board since October 2019. Prior to this, Mr. Browne served as Chief Revenue Officer of CCS Medical, Inc., a provider of home delivery medical supplies, from September 2014 to June 2019. Prior to CCS Medical, Mr. Browne served as Chief Operating Officer of The Kini Group, an integrated cloud based software analytics and advisory firm, from March 2013 to August 2014. From November 2007 to March 2016, Mr. Browne served as President and Chief Executive Officer and a director of Neuro Resource Group, a venture start up medical device company that was sold to a strategic buyer. In other roles, Mr. Browne served as President, Miltex Surgical Instrument Division for Integra LifeSciences Holdings Corporation, a publicly held medical device company that acquired Miltex Holdings, Inc. Mr. Browne served as Vice President, Sales and Marketing of Esurg.com, an e commerce company serving physician and ambulatory surgery markets. Prior to Esurg.com, Mr. Browne served as Senior Vice President, Health Systems Division of McKesson Corporation, a drug company, and prior to McKesson, served in various positions with increasing responsibility at Baxter Healthcare. Mr. Browne holds a Master of Business Administration from the Kellogg School of Management at Northwestern University and a Bachelor of Science degree, with a major in Finance and minor in Statistics, from Boston University.
- Jonn R. Beeson
-
Jonn Beeson，自2023年5月1日起担任Xtant Medical Holdings, Inc.董事会成员。比森先生是全球律师事务所众达律师事务所的合伙人，自1996年以来一直从事公司法业务。他的工作重点是并购、资产剥离、收购、融资、证券交易、公司治理和股东维权问题。Beeson先生代表各种企业客户，在生命科学、技术和软件行业最为活跃，拥有与众多医疗设备公司合作的丰富经验。Beeson先生拥有加州大学欧文分校的理学学士学位和宾夕法尼亚大学的法学博士学位。
Jonn R. Beeson has served as a member of Xtant Medical Holdings, Inc.'s Board since May 2023. Mr. Beeson is a partner with Jones Day, a global law firm, and has been practicing corporate law since 1996. His practice focuses on mergers and acquisitions, divestitures, takeovers, capital raising, securities transactions, corporate governance, and stockholder activism matters. Mr. Beeson represents a variety of corporate clients and is most active in the life sciences, technology and software industries, with significant experience working with a wide range of medical device companies. Mr. Beeson holds a Bachelor of Science degree from the University of California, Irvine, and a Juris Doctor from the University of Pennsylvania. - Jonn Beeson，自2023年5月1日起担任Xtant Medical Holdings, Inc.董事会成员。比森先生是全球律师事务所众达律师事务所的合伙人，自1996年以来一直从事公司法业务。他的工作重点是并购、资产剥离、收购、融资、证券交易、公司治理和股东维权问题。Beeson先生代表各种企业客户，在生命科学、技术和软件行业最为活跃，拥有与众多医疗设备公司合作的丰富经验。Beeson先生拥有加州大学欧文分校的理学学士学位和宾夕法尼亚大学的法学博士学位。
- Jonn R. Beeson has served as a member of Xtant Medical Holdings, Inc.'s Board since May 2023. Mr. Beeson is a partner with Jones Day, a global law firm, and has been practicing corporate law since 1996. His practice focuses on mergers and acquisitions, divestitures, takeovers, capital raising, securities transactions, corporate governance, and stockholder activism matters. Mr. Beeson represents a variety of corporate clients and is most active in the life sciences, technology and software industries, with significant experience working with a wide range of medical device companies. Mr. Beeson holds a Bachelor of Science degree from the University of California, Irvine, and a Juris Doctor from the University of Pennsylvania.
- Abhinav Jain
-
Abhinav Jain曾担任Nantahala Capital Management，LLC的分析师，该公司是一家投资管理公司，专注于各个领域的投资，包括特种和仿制药以及医疗技术，并且是该公司49.1%已发行普通股（“Nantahala”）的实益拥有人。从2015年到2017年，Jain先生是另类资产管理公司Angelo，Gordon & Co.的合伙人。在Angelo，Gordon & Co.，Jain先生专注于私募股权和结构性信贷投资。Jain先生目前担任专业制药公司Aytu BioPharma, Inc.（NASDAQ：AYTU）和专业制药公司Talphera，Inc.（NASDAQ：TLPH）的董事会成员。他于2012年毕业于麻省理工学院化学-生物工程专业，并于2019年毕业于宾夕法尼亚大学沃顿商学院，获得金融和创业管理专业荣誉工商管理硕士学位。
Abhinav Jain has served as a member of Xtant Medical Holdings, Inc.'s Board since August 1, 2025. Since July 2019, Mr. Jain has served as an Analyst at Nantahala Capital Management, LLC, an investment management company focused on investments in various sectors, including specialty and generic pharmaceuticals and medtech, and the beneficial owner of 48.8% of Xtant Medical Holdings, Inc.'s outstanding common stock. Mr. Jain was appointed to the Board at the request of Nantahala and upon a determination by the Board that his appointment is in the best interests of the Company and Xtant Medical Holdings, Inc.'s stockholders. From 2015 to 2017, Mr. Jain was an Associate at Angelo, Gordon & Co., an alternative asset manager. At Angelo, Gordon & Co., Mr. Jain focused on private equity and structured credit investments. Mr. Jain currently serves as a member of the board of directors of Aytu Biopharma, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company, Talphera, Inc. (NASDAQ: TLPH), a specialty pharmaceutical company, and Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX), a specialty pharmaceutical company. He holds a Bachelor of Science degree in Chemical Biological Engineering from Massachusetts Institute of Technology and a Master of Business Administration with honors in Finance and Entrepreneurial Management from The Wharton School of the University of Pennsylvania. - Abhinav Jain曾担任Nantahala Capital Management，LLC的分析师，该公司是一家投资管理公司，专注于各个领域的投资，包括特种和仿制药以及医疗技术，并且是该公司49.1%已发行普通股（“Nantahala”）的实益拥有人。从2015年到2017年，Jain先生是另类资产管理公司Angelo，Gordon & Co.的合伙人。在Angelo，Gordon & Co.，Jain先生专注于私募股权和结构性信贷投资。Jain先生目前担任专业制药公司Aytu BioPharma, Inc.（NASDAQ：AYTU）和专业制药公司Talphera，Inc.（NASDAQ：TLPH）的董事会成员。他于2012年毕业于麻省理工学院化学-生物工程专业，并于2019年毕业于宾夕法尼亚大学沃顿商学院，获得金融和创业管理专业荣誉工商管理硕士学位。
- Abhinav Jain has served as a member of Xtant Medical Holdings, Inc.'s Board since August 1, 2025. Since July 2019, Mr. Jain has served as an Analyst at Nantahala Capital Management, LLC, an investment management company focused on investments in various sectors, including specialty and generic pharmaceuticals and medtech, and the beneficial owner of 48.8% of Xtant Medical Holdings, Inc.'s outstanding common stock. Mr. Jain was appointed to the Board at the request of Nantahala and upon a determination by the Board that his appointment is in the best interests of the Company and Xtant Medical Holdings, Inc.'s stockholders. From 2015 to 2017, Mr. Jain was an Associate at Angelo, Gordon & Co., an alternative asset manager. At Angelo, Gordon & Co., Mr. Jain focused on private equity and structured credit investments. Mr. Jain currently serves as a member of the board of directors of Aytu Biopharma, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company, Talphera, Inc. (NASDAQ: TLPH), a specialty pharmaceutical company, and Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX), a specialty pharmaceutical company. He holds a Bachelor of Science degree in Chemical Biological Engineering from Massachusetts Institute of Technology and a Master of Business Administration with honors in Finance and Entrepreneurial Management from The Wharton School of the University of Pennsylvania.
- Tyler P. Lipschultz
-
Tyler P. Lipschultz， 2011年11月起担任全球运营执行副总裁。在此之前，Lipschultz先生从2011年1月到2011年11月担任生物制剂执行副总裁。从2008年7月到2010年12月，他担任生物制剂高级副总裁。从2002年3月到2008年6月，他是Spine Wave（一家风险投资的脊柱植入公司）的创始人，并担任多个职位，包括执行副总裁和总经理。Lipschultz先生在医疗器械行业拥有超过20年的经验，包括：Protostar（医疗器械孵化器）的董事和VERTx（由Protostar创立的私人公司，后来与Spine Wave合并）的总裁；在US Bancorp Piper Jaffray， Inc.担任股票研究分析师，专注于骨科和脊柱市场；在DePuy， Smith & Nephew plc和Stryker， Inc.担任各种营销职位。他持有Kalamazoo College的经济学和工商管理学士学位，以及Purdue 大学的工商管理硕士学位。
Tyler P. Lipschultz has served as a member of Xtant Medical Holdings, Inc.'s Board since August 1, 2025. Mr. Lipschultz was appointed to the Board at the request of Nantahala and upon a determination by the Board that his appointment is in the best interests of the Company and Xtant Medical Holdings, Inc.'s stockholders. Mr. Lipschultz has over 35 years of leadership experience in orthopaedics, spine, and biologics. He currently serves as President of LocateBio, Inc., a U.S. subsidiary of a biotechnology company in England, a position he has held since November 2024. Prior to LocateBio, Mr. Lipschultz served as President, Global Biologics at Orthofix Medical Inc., a global medical technology company, from January 2023 until July 2025. Prior to Orthofix, Mr. Lipschultz served as Senior Vice President, Orthobiologics and Business Development of SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, from February 2018 until its acquisition by Orthofix in January 2023, and prior to that position, served as Vice President, Orthobiologics and Business Development of SeaSpine from July 2015 to February 2018. From June 2008 to March 2015, Mr. Lipschultz held positions of increasing responsibility at NuVasive, Inc., a publicly traded medical device company, most recently serving as its Executive Vice President, Global Operations, and, prior to that, Executive Vice President, Biologics. Prior to joining NuVasive, Mr. Lipschultz was a director at ProtoStar, a medical device incubator that formed Annulex, CVRx, and VERTx, which he co founded. In 2002, VERTx merged with Spine Wave, where Mr. Lipschultz subsequently served in a variety of roles, including Executive Vice President and General Manager of the mechanical business. Prior to ProtoStar, Mr. Lipschultz held the position of Equity Research Analyst at Piper Jaffray and served in various marketing/product management roles at Stryker Corporation, Smith & Nephew plc, and DePuy. Mr. Lipschultz received a Bachelor of Arts degree in Economics and Business Administration from Kalamazoo College and a Master of Business Administration from the executive program at Krannert School of Management at Purdue University. - Tyler P. Lipschultz， 2011年11月起担任全球运营执行副总裁。在此之前，Lipschultz先生从2011年1月到2011年11月担任生物制剂执行副总裁。从2008年7月到2010年12月，他担任生物制剂高级副总裁。从2002年3月到2008年6月，他是Spine Wave（一家风险投资的脊柱植入公司）的创始人，并担任多个职位，包括执行副总裁和总经理。Lipschultz先生在医疗器械行业拥有超过20年的经验，包括：Protostar（医疗器械孵化器）的董事和VERTx（由Protostar创立的私人公司，后来与Spine Wave合并）的总裁；在US Bancorp Piper Jaffray， Inc.担任股票研究分析师，专注于骨科和脊柱市场；在DePuy， Smith & Nephew plc和Stryker， Inc.担任各种营销职位。他持有Kalamazoo College的经济学和工商管理学士学位，以及Purdue 大学的工商管理硕士学位。
- Tyler P. Lipschultz has served as a member of Xtant Medical Holdings, Inc.'s Board since August 1, 2025. Mr. Lipschultz was appointed to the Board at the request of Nantahala and upon a determination by the Board that his appointment is in the best interests of the Company and Xtant Medical Holdings, Inc.'s stockholders. Mr. Lipschultz has over 35 years of leadership experience in orthopaedics, spine, and biologics. He currently serves as President of LocateBio, Inc., a U.S. subsidiary of a biotechnology company in England, a position he has held since November 2024. Prior to LocateBio, Mr. Lipschultz served as President, Global Biologics at Orthofix Medical Inc., a global medical technology company, from January 2023 until July 2025. Prior to Orthofix, Mr. Lipschultz served as Senior Vice President, Orthobiologics and Business Development of SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, from February 2018 until its acquisition by Orthofix in January 2023, and prior to that position, served as Vice President, Orthobiologics and Business Development of SeaSpine from July 2015 to February 2018. From June 2008 to March 2015, Mr. Lipschultz held positions of increasing responsibility at NuVasive, Inc., a publicly traded medical device company, most recently serving as its Executive Vice President, Global Operations, and, prior to that, Executive Vice President, Biologics. Prior to joining NuVasive, Mr. Lipschultz was a director at ProtoStar, a medical device incubator that formed Annulex, CVRx, and VERTx, which he co founded. In 2002, VERTx merged with Spine Wave, where Mr. Lipschultz subsequently served in a variety of roles, including Executive Vice President and General Manager of the mechanical business. Prior to ProtoStar, Mr. Lipschultz held the position of Equity Research Analyst at Piper Jaffray and served in various marketing/product management roles at Stryker Corporation, Smith & Nephew plc, and DePuy. Mr. Lipschultz received a Bachelor of Arts degree in Economics and Business Administration from Kalamazoo College and a Master of Business Administration from the executive program at Krannert School of Management at Purdue University.
- Stavros G. Vizirgianakis
-
Stavros G. Vizirgianakis，自2022年8月起担任董事会成员。Vizirgianakis先生于2022年8月因Xtant Medical Holdings， Inc.的私募而当选为董事会成员。Vizirgianakis先生是Misonix， Inc.（医疗设备公司，Bioventus Inc.于2021年收购）的前首席执行官。Vizirgianakis先生在医疗设备领域拥有杰出的职业生涯，曾担任United States Surgical Corporation撒哈拉以南非洲地区的销售总监，后来担任Tyco Healthcare南非总经理。2006年，Vizirgianakis先生共同创立了Surgical Innovations，该公司已成为非洲地区最大的私营医疗设备分销商之一，现在是约翰内斯堡证券交易所上市实体Ascendis Health的一部分。Vizirgianakis先生从2014年1月到2016年7月担任Ascendis Medical的总经理。Vizirgianakis先生从2016年9月到2021年10月担任Misonix的总裁兼首席执行官。Vizirgianakis先生目前担任Apyx Medical Corporation （NASDAQ： Apyx）（一家先进的能源技术公司）的董事会主席，以及Medinotec， Inc. （OTCQX： MDNC）（一家医疗设备公司）的董事会成员。他曾担任Bioventus Inc.和Tenaxis Medical， Inc.的董事会成员，是该领域众多医疗设备初创公司和成熟公司的战略投资者和顾问。Vizirgianakis先生拥有South Africa大学的商业学位。
Stavros G. Vizirgianakis has served as a member of and Chairman of the Board since August 2022. Mr. Vizirgianakis was elected to the Board in connection with Xtant Medical Holdings, Inc.'s private placement in August 2022. Mr. Vizirgianakis is the former Chief Executive Officer of Misonix, Inc., a medical device company that Bioventus Inc. acquired in 2021. Mr. Vizirgianakis has a distinguished career in the medical devices field having worked for United States Surgical Corporation as director of sales for sub Saharan Africa and later Tyco Healthcare in the capacity of General Manager South Africa. In 2006, Mr. Vizirgianakis co founded Surgical Innovations, which has become one of the largest privately owned medical device distributors in the African region, and now part of the Johannesburg Stock Exchange listed entity Ascendis Health. Mr. Vizirgianakis was Managing Director of Ascendis Medical from January 2014 through July 2016. Mr. Vizirgianakis served as the President and Chief Executive Officer of Misonix from September 2016 through October 2021. Mr. Vizirgianakis currently serves as Chair of the board of directors of Apyx Medical Corporation (NASDAQ: APYX), an advanced energy technology company, and as a member of the board of directors of Medinotec, Inc. (OTCQX: MDNC), a medical device company. He previously served on the board of directors of Bioventus Inc. and Tenaxis Medical, Inc. and is a strategic investor and advisor to numerous medical device startups and established companies in this field. Mr. Vizirgianakis has a Degree in Commerce from the University of South Africa. - Stavros G. Vizirgianakis，自2022年8月起担任董事会成员。Vizirgianakis先生于2022年8月因Xtant Medical Holdings， Inc.的私募而当选为董事会成员。Vizirgianakis先生是Misonix， Inc.（医疗设备公司，Bioventus Inc.于2021年收购）的前首席执行官。Vizirgianakis先生在医疗设备领域拥有杰出的职业生涯，曾担任United States Surgical Corporation撒哈拉以南非洲地区的销售总监，后来担任Tyco Healthcare南非总经理。2006年，Vizirgianakis先生共同创立了Surgical Innovations，该公司已成为非洲地区最大的私营医疗设备分销商之一，现在是约翰内斯堡证券交易所上市实体Ascendis Health的一部分。Vizirgianakis先生从2014年1月到2016年7月担任Ascendis Medical的总经理。Vizirgianakis先生从2016年9月到2021年10月担任Misonix的总裁兼首席执行官。Vizirgianakis先生目前担任Apyx Medical Corporation （NASDAQ： Apyx）（一家先进的能源技术公司）的董事会主席，以及Medinotec， Inc. （OTCQX： MDNC）（一家医疗设备公司）的董事会成员。他曾担任Bioventus Inc.和Tenaxis Medical， Inc.的董事会成员，是该领域众多医疗设备初创公司和成熟公司的战略投资者和顾问。Vizirgianakis先生拥有South Africa大学的商业学位。
- Stavros G. Vizirgianakis has served as a member of and Chairman of the Board since August 2022. Mr. Vizirgianakis was elected to the Board in connection with Xtant Medical Holdings, Inc.'s private placement in August 2022. Mr. Vizirgianakis is the former Chief Executive Officer of Misonix, Inc., a medical device company that Bioventus Inc. acquired in 2021. Mr. Vizirgianakis has a distinguished career in the medical devices field having worked for United States Surgical Corporation as director of sales for sub Saharan Africa and later Tyco Healthcare in the capacity of General Manager South Africa. In 2006, Mr. Vizirgianakis co founded Surgical Innovations, which has become one of the largest privately owned medical device distributors in the African region, and now part of the Johannesburg Stock Exchange listed entity Ascendis Health. Mr. Vizirgianakis was Managing Director of Ascendis Medical from January 2014 through July 2016. Mr. Vizirgianakis served as the President and Chief Executive Officer of Misonix from September 2016 through October 2021. Mr. Vizirgianakis currently serves as Chair of the board of directors of Apyx Medical Corporation (NASDAQ: APYX), an advanced energy technology company, and as a member of the board of directors of Medinotec, Inc. (OTCQX: MDNC), a medical device company. He previously served on the board of directors of Bioventus Inc. and Tenaxis Medical, Inc. and is a strategic investor and advisor to numerous medical device startups and established companies in this field. Mr. Vizirgianakis has a Degree in Commerce from the University of South Africa.
- John K. Bakewell
-
John K. Bakewell，2014年6月，他加入Lantheus担任公司首席财务官。2013年6月至2014年5月，他曾担任Interline Brands, Inc., or Interline的首席财务官。加入Interline之前，2010年1月至2011年12月，他担任RegionalCare Hospital Partners的执行副总裁和首席财务官。此外，2000至2009年，他在全球整形外科医疗设备制造商Wright Medical Group担任相同职位。1998至2000年，他担任Altra Energy Technologies的首席财务官；1993至1998年担任Cyberonics, Inc.的首席财务官；1990至1993年担任Zeos International的首席财务官。他还是Keystone Dental, Inc.的董事会成员。他在Northern Iowa大学获得会计学学士学位，是明尼苏达州和爱荷华州的执业注册会计师。
John K. Bakewell has served as a member of Xtant Medical Holdings, Inc.'s Board since February 2018. He was initially elected to the Board in connection with Xtant Medical Holdings, Inc.'s restructuring in February 2018. Mr. Bakewell is a strategic executive with more than 30 years of experience in senior executive roles and as a board member of several medical technology companies. He currently serves on the board of directors of Treace Medical Concepts, Inc. (NASDAQ: TMCI), a medical device company. Mr. Bakewell most recently held the position of Chief Financial Officer of Exact Sciences Corporation, a molecular diagnostics company recently acquired by Abbott Laboratories, and previously Chief Financial Officer of Lantheus Holdings, Inc. (NASDAQ: LNTH), a diagnostic medical imaging company. Mr. Bakewell also previously served in Chief Financial Officer positions at Interline Brands, Inc., RegionalCare Hospital Partners, Wright Medical Group, Inc., which was acquired by Stryker Corporation (NYSE: SYK) in November 2020, Cyberonics, Inc., now part of LivaNova PLC (NASDAQ: LIVN), Altra Energy Technologies, Inc. and ZEOS International, Ltd. He began his career in the public accounting profession, serving seven years, collectively, with Ernst & Young and KPMG Peat Marwick. Mr. Bakewell previously served on the board of directors of Neuronetics, Inc. (NASDAQ: STIM), a public medical device company; Entellus Medical, Inc., a public ENT focused medical device company, until its acquisition by Stryker Corporation; ev3 Inc., a public endovascular medical device company, until its acquisition by Covidien plc; and Corindus Vascular Robotics, Inc., a public cardiovascular robotics medical technology company and now a Siemens Healthineers company. Mr. Bakewell holds a Bachelor of Arts in Accounting from the University of Northern Iowa and is a certified public accountant (current status inactive). - John K. Bakewell，2014年6月，他加入Lantheus担任公司首席财务官。2013年6月至2014年5月，他曾担任Interline Brands, Inc., or Interline的首席财务官。加入Interline之前，2010年1月至2011年12月，他担任RegionalCare Hospital Partners的执行副总裁和首席财务官。此外，2000至2009年，他在全球整形外科医疗设备制造商Wright Medical Group担任相同职位。1998至2000年，他担任Altra Energy Technologies的首席财务官；1993至1998年担任Cyberonics, Inc.的首席财务官；1990至1993年担任Zeos International的首席财务官。他还是Keystone Dental, Inc.的董事会成员。他在Northern Iowa大学获得会计学学士学位，是明尼苏达州和爱荷华州的执业注册会计师。
- John K. Bakewell has served as a member of Xtant Medical Holdings, Inc.'s Board since February 2018. He was initially elected to the Board in connection with Xtant Medical Holdings, Inc.'s restructuring in February 2018. Mr. Bakewell is a strategic executive with more than 30 years of experience in senior executive roles and as a board member of several medical technology companies. He currently serves on the board of directors of Treace Medical Concepts, Inc. (NASDAQ: TMCI), a medical device company. Mr. Bakewell most recently held the position of Chief Financial Officer of Exact Sciences Corporation, a molecular diagnostics company recently acquired by Abbott Laboratories, and previously Chief Financial Officer of Lantheus Holdings, Inc. (NASDAQ: LNTH), a diagnostic medical imaging company. Mr. Bakewell also previously served in Chief Financial Officer positions at Interline Brands, Inc., RegionalCare Hospital Partners, Wright Medical Group, Inc., which was acquired by Stryker Corporation (NYSE: SYK) in November 2020, Cyberonics, Inc., now part of LivaNova PLC (NASDAQ: LIVN), Altra Energy Technologies, Inc. and ZEOS International, Ltd. He began his career in the public accounting profession, serving seven years, collectively, with Ernst & Young and KPMG Peat Marwick. Mr. Bakewell previously served on the board of directors of Neuronetics, Inc. (NASDAQ: STIM), a public medical device company; Entellus Medical, Inc., a public ENT focused medical device company, until its acquisition by Stryker Corporation; ev3 Inc., a public endovascular medical device company, until its acquisition by Covidien plc; and Corindus Vascular Robotics, Inc., a public cardiovascular robotics medical technology company and now a Siemens Healthineers company. Mr. Bakewell holds a Bachelor of Arts in Accounting from the University of Northern Iowa and is a certified public accountant (current status inactive).
高管简历
中英对照 | 中文 | 英文- Sean E. Browne
SeanE.Browne于2019年10月7日被任命为我们的总裁兼首席执行官，并自2019年10月30日起担任董事会成员。在此之前，Browne先生于2014年9月至2019年6月担任上门医疗用品提供商CCS Medical，Inc.的首席营收官。加入CCS Medical之前，Browne从2013年3月到2014年8月担任Kini Group（一家集成的基于云的软件分析和咨询公司）首席运营官。从2007年11月至2016年3月，Browne先生担任Neuro Resource Group的总裁兼首席执行官兼董事，Neuro Resource Group是一家风险初创医疗设备公司，已出售给战略买家。在其他职位上，布朗先生曾担任Integra Lifesciences Holdings Corporation Miltex手术器械部门的总裁，该公司是一家上市医疗设备公司，收购了Miltex Holdings，Inc.。Browne先生曾担任eSurg.com的销售与市场营销Vice President，这是一家为医生和门诊手术市场提供服务的电子商务公司。在加入eSurg.com之前，Browne先生曾担任麦克森公司公司（一家制药公司）的高级副总裁，健康系统部，在加入McKesson公司之前，他曾在百特梦百合公司担任多个职位，并承担越来越多的责任。Browne先生拥有西北大学凯洛格管理学院（Kellogg School of Management at Northwestern University）的工商管理硕士学位和波士顿大学（Boston University）的理学士学位，主修金融和辅修统计学。
Sean E. Browne has served as Xtant Medical Holdings, Inc.'s President and Chief Executive Officer since October 2019 and as a member of Xtant Medical Holdings, Inc.'s Board since October 2019. Prior to this, Mr. Browne served as Chief Revenue Officer of CCS Medical, Inc., a provider of home delivery medical supplies, from September 2014 to June 2019. Prior to CCS Medical, Mr. Browne served as Chief Operating Officer of The Kini Group, an integrated cloud based software analytics and advisory firm, from March 2013 to August 2014. From November 2007 to March 2016, Mr. Browne served as President and Chief Executive Officer and a director of Neuro Resource Group, a venture start up medical device company that was sold to a strategic buyer. In other roles, Mr. Browne served as President, Miltex Surgical Instrument Division for Integra LifeSciences Holdings Corporation, a publicly held medical device company that acquired Miltex Holdings, Inc. Mr. Browne served as Vice President, Sales and Marketing of Esurg.com, an e commerce company serving physician and ambulatory surgery markets. Prior to Esurg.com, Mr. Browne served as Senior Vice President, Health Systems Division of McKesson Corporation, a drug company, and prior to McKesson, served in various positions with increasing responsibility at Baxter Healthcare. Mr. Browne holds a Master of Business Administration from the Kellogg School of Management at Northwestern University and a Bachelor of Science degree, with a major in Finance and minor in Statistics, from Boston University.- SeanE.Browne于2019年10月7日被任命为我们的总裁兼首席执行官，并自2019年10月30日起担任董事会成员。在此之前，Browne先生于2014年9月至2019年6月担任上门医疗用品提供商CCS Medical，Inc.的首席营收官。加入CCS Medical之前，Browne从2013年3月到2014年8月担任Kini Group（一家集成的基于云的软件分析和咨询公司）首席运营官。从2007年11月至2016年3月，Browne先生担任Neuro Resource Group的总裁兼首席执行官兼董事，Neuro Resource Group是一家风险初创医疗设备公司，已出售给战略买家。在其他职位上，布朗先生曾担任Integra Lifesciences Holdings Corporation Miltex手术器械部门的总裁，该公司是一家上市医疗设备公司，收购了Miltex Holdings，Inc.。Browne先生曾担任eSurg.com的销售与市场营销Vice President，这是一家为医生和门诊手术市场提供服务的电子商务公司。在加入eSurg.com之前，Browne先生曾担任麦克森公司公司（一家制药公司）的高级副总裁，健康系统部，在加入McKesson公司之前，他曾在百特梦百合公司担任多个职位，并承担越来越多的责任。Browne先生拥有西北大学凯洛格管理学院（Kellogg School of Management at Northwestern University）的工商管理硕士学位和波士顿大学（Boston University）的理学士学位，主修金融和辅修统计学。
- Sean E. Browne has served as Xtant Medical Holdings, Inc.'s President and Chief Executive Officer since October 2019 and as a member of Xtant Medical Holdings, Inc.'s Board since October 2019. Prior to this, Mr. Browne served as Chief Revenue Officer of CCS Medical, Inc., a provider of home delivery medical supplies, from September 2014 to June 2019. Prior to CCS Medical, Mr. Browne served as Chief Operating Officer of The Kini Group, an integrated cloud based software analytics and advisory firm, from March 2013 to August 2014. From November 2007 to March 2016, Mr. Browne served as President and Chief Executive Officer and a director of Neuro Resource Group, a venture start up medical device company that was sold to a strategic buyer. In other roles, Mr. Browne served as President, Miltex Surgical Instrument Division for Integra LifeSciences Holdings Corporation, a publicly held medical device company that acquired Miltex Holdings, Inc. Mr. Browne served as Vice President, Sales and Marketing of Esurg.com, an e commerce company serving physician and ambulatory surgery markets. Prior to Esurg.com, Mr. Browne served as Senior Vice President, Health Systems Division of McKesson Corporation, a drug company, and prior to McKesson, served in various positions with increasing responsibility at Baxter Healthcare. Mr. Browne holds a Master of Business Administration from the Kellogg School of Management at Northwestern University and a Bachelor of Science degree, with a major in Finance and minor in Statistics, from Boston University.
- Scott C. Neils
Scott C. Neils，自2022年6月起担任Xtant Medical Holdings, Inc.首席财务官，在此之前于2022年1月至2022年6月担任Xtant Medical Holdings, Inc.临时首席财务官，并于2019年8月至2022年1月担任Xtant Medical Holdings, Inc.财务总监。Neils先生在公共会计和公司财务方面有15年的经验。在担任这一职务期间，Neils先生获得了管理Xtant Medical Holdings，Inc.财务和会计职能的丰富经验。在加入Xtant之前，Neils先生曾于2015年11月至2019年8月在咨询、税务和鉴证公司Baker Tilly US，LLP（前身为Baker Tilly Virchow Krause，LLP）担任审计高级经理。在担任该职位之前，Neils先生于2007年9月至2015年11月在会计和咨询机构Grant Thornton LLP任职，最近担任审计经理。Neils先生是注册会计师。他拥有明尼苏达大学卡尔森管理学院会计学商业学士学位和会计学硕士学位。
Scott C. Neils has served as Xtant Medical Holdings, Inc.'s Chief Financial Officer since June 2022 and was appointed as Xtant Medical Holdings, Inc.'s Assistant Secretary in September 2025. Prior to that, served as Xtant Medical Holdings, Inc.'s Interim Chief Financial Officer from January 2022 to June 2022 and as Xtant Medical Holdings, Inc.'s Controller from August 2019 until January 2022. Mr. Neils has over 15 years of experience focused on public accounting and corporate finance. In this role, Mr. Neils gained extensive experience managing Xtant Medical Holdings, Inc.'s finance and accounting functions. Prior to joining Xtant, Mr. Neils served as Audit Senior Manager at Baker Tilly US, LLP (formerly Baker Tilly Virchow Krause, LLP), an advisory, tax and assurance firm, from November 2015 to August 2019. Prior to that position, Mr. Neils was at Grant Thornton LLP, an accounting and advisory organization, from September 2007 to November 2015, most recently as Audit Manager. Mr. Neils is a Certified Public Accountant. He holds a Bachelor of Science in Business in Accounting and a Master of Accountancy from the Carlson School of Management at the University of Minnesota.- Scott C. Neils，自2022年6月起担任Xtant Medical Holdings, Inc.首席财务官，在此之前于2022年1月至2022年6月担任Xtant Medical Holdings, Inc.临时首席财务官，并于2019年8月至2022年1月担任Xtant Medical Holdings, Inc.财务总监。Neils先生在公共会计和公司财务方面有15年的经验。在担任这一职务期间，Neils先生获得了管理Xtant Medical Holdings，Inc.财务和会计职能的丰富经验。在加入Xtant之前，Neils先生曾于2015年11月至2019年8月在咨询、税务和鉴证公司Baker Tilly US，LLP（前身为Baker Tilly Virchow Krause，LLP）担任审计高级经理。在担任该职位之前，Neils先生于2007年9月至2015年11月在会计和咨询机构Grant Thornton LLP任职，最近担任审计经理。Neils先生是注册会计师。他拥有明尼苏达大学卡尔森管理学院会计学商业学士学位和会计学硕士学位。
- Scott C. Neils has served as Xtant Medical Holdings, Inc.'s Chief Financial Officer since June 2022 and was appointed as Xtant Medical Holdings, Inc.'s Assistant Secretary in September 2025. Prior to that, served as Xtant Medical Holdings, Inc.'s Interim Chief Financial Officer from January 2022 to June 2022 and as Xtant Medical Holdings, Inc.'s Controller from August 2019 until January 2022. Mr. Neils has over 15 years of experience focused on public accounting and corporate finance. In this role, Mr. Neils gained extensive experience managing Xtant Medical Holdings, Inc.'s finance and accounting functions. Prior to joining Xtant, Mr. Neils served as Audit Senior Manager at Baker Tilly US, LLP (formerly Baker Tilly Virchow Krause, LLP), an advisory, tax and assurance firm, from November 2015 to August 2019. Prior to that position, Mr. Neils was at Grant Thornton LLP, an accounting and advisory organization, from September 2007 to November 2015, most recently as Audit Manager. Mr. Neils is a Certified Public Accountant. He holds a Bachelor of Science in Business in Accounting and a Master of Accountancy from the Carlson School of Management at the University of Minnesota.
- Mark A. Schallenberger
Mark A. Schallenberger被任命为Xtant Medical Holdings, Inc.首席运营官，自2023年1月16日起生效。在此之前，Schallenberger先生于2019年6月至2023年1月担任医疗技术制造商Surgenex LLC的首席运营官。在加入Surgenex之前，Schallenberger先生于2016年2月至2019年6月担任组织银行DCI Donor Services Tissue Bank的营销和产品开发高级总监。在加入DCI捐助服务组织银行之前，Schallenberger先生曾在2010年9月至2016年2月期间担任多个职位，并承担了越来越多的责任，最终在Xtant Medical Holdings，Inc.的科学事务总监（前身为Bacterin International Holdings，Inc.）任职。Schallenberger先生拥有斯克里普斯研究所化学生物学理学硕士学位和蒙大拿大学化学理学学士学位。
Mark A. Schallenberger was appointed Xtant Medical Holdings, Inc.'s Chief Operating Officer in April 2025, and prior to that position, served as Chief Operations Officer since January 2023. Prior to this, Mr. Schallenberger served as Chief Operations Officer of Surgenex LLC, a medical technology manufacturer, from June 2019 to January 2023. Prior to Surgenex, Mr. Schallenberger served as Senior Director of Marketing & Product Development of DCI Donor Services Tissue Bank, a tissue bank, from February 2016 to June 2019. Prior to DCI Donor Services Tissue Bank, Mr. Schallenberger served various roles with increasing responsibility from September 2010 to February 2016 culminating with Director of Scientific Affairs with Xtant Medical Holdings, Inc. formerly Bacterin International Holdings, Inc. Mr. Schallenberger holds a Master of Science in Chemical Biology from The Scripps Research Institute and a Bachelor of Science degree in Chemistry from the University of Montana.- Mark A. Schallenberger被任命为Xtant Medical Holdings, Inc.首席运营官，自2023年1月16日起生效。在此之前，Schallenberger先生于2019年6月至2023年1月担任医疗技术制造商Surgenex LLC的首席运营官。在加入Surgenex之前，Schallenberger先生于2016年2月至2019年6月担任组织银行DCI Donor Services Tissue Bank的营销和产品开发高级总监。在加入DCI捐助服务组织银行之前，Schallenberger先生曾在2010年9月至2016年2月期间担任多个职位，并承担了越来越多的责任，最终在Xtant Medical Holdings，Inc.的科学事务总监（前身为Bacterin International Holdings，Inc.）任职。Schallenberger先生拥有斯克里普斯研究所化学生物学理学硕士学位和蒙大拿大学化学理学学士学位。
- Mark A. Schallenberger was appointed Xtant Medical Holdings, Inc.'s Chief Operating Officer in April 2025, and prior to that position, served as Chief Operations Officer since January 2023. Prior to this, Mr. Schallenberger served as Chief Operations Officer of Surgenex LLC, a medical technology manufacturer, from June 2019 to January 2023. Prior to Surgenex, Mr. Schallenberger served as Senior Director of Marketing & Product Development of DCI Donor Services Tissue Bank, a tissue bank, from February 2016 to June 2019. Prior to DCI Donor Services Tissue Bank, Mr. Schallenberger served various roles with increasing responsibility from September 2010 to February 2016 culminating with Director of Scientific Affairs with Xtant Medical Holdings, Inc. formerly Bacterin International Holdings, Inc. Mr. Schallenberger holds a Master of Science in Chemical Biology from The Scripps Research Institute and a Bachelor of Science degree in Chemistry from the University of Montana.